ZANTAC SWITCH TO NONPRESCRIPTION STATUS IN U.K. PROPOSED
This article was originally published in The Tan Sheet
Executive Summary
ZANTAC SWITCH TO NONPRESCRIPTION STATUS IN U.K. PROPOSED by that country's Medicines Control Agency in a July 1 "consultation letter" offered to interested parties for comment. Under an agreement announced in August 1993, the nonprescription version of Glaxo's Zantac (ranitidine) will be marketed by Warner Wellcome in the U.K. The product will be indicated for short-term symptomatic relief of heartburn, dyspepsia and hyperacidity as an OTC.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning